Company / SG&A Expense
Amphstar Pharmaceuticals, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$85.9M
FY2025
5-year range
$45.1M / $85.9M
FY2021-FY2025
Trend
+51.5%
vs FY2024
Sector context
#122 of 213
Health Care
What the data says
At $86M, Amphstar Pharmaceuticals, Inc.'s sg&a expense ranks #92 of 213 in the Health Care sector. SG&A Expense has increased for 3 consecutive years, from $45M in FY2022 to $86M in FY2025.
Based on SEC 10-K filings.
$86M in FY2025 with a 5-year CAGR of +11.3%.
Increased from $52M to $86M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +24.0%
- 5-Year CAGR
- +11.3%
- 10-Year CAGR
- -
Sector benchmark
#92 of 213 in Health CareTop 43% of 213This company $85.9M Sector average $722.3M
▼
-88.1% below sector average
Key checks
Key Insights
- Amphstar Pharmaceuticals, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +11.3%, indicating consistent growth.
- In FY2025, sg&a expense increased 51.5% year-over-year.
- Ranks #122 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $85.9M | +51.5% |
| FY2024 | $56.7M | +10.1% |
| FY2023 | $51.5M | +14.4% |
| FY2022 | $45.1M | -12.4% |
| FY2021 | $51.4M | +2.1% |
| FY2020 | $50.4M | +0.2% |
| FY2019 | $50.3M | +0.8% |
| FY2018 | $49.9M | +12.2% |
| FY2017 | $44.5M | +6.3% |
| FY2016 | $41.8M | +0.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026